Clinical impact of adjuvant chemotherapy and regimen selection in Stage III colorectal cancer with impaired performance status: a multicenter cohort study
Authors:
- 16 July 2026
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (10) , 2301-2311
Abstract
Background The optimal use of adjuvant chemotherapy (ACT) in patients with impaired performance status (PS) has not been reliably determined, particularly regarding intensification of treatment with oxaliplatin (OX). In this study, we evaluated the clinical impact of ACT and OX in patients with Stage III colorectal cancer (CRC) and impaired PS. Methods The cohort of this multicenter retrospective study comprised 566 patients with Stage III CRC and PS ≥ 1 who had undergone curative resection. Propensity score matching was used to compare outcomes between ACT (+) and ACT (−) groups. Additionally, stabilized inverse probability of treatment weighting was performed to compare outcomes of fluoropyrimidine (FP) monotherapy and OX-based regimens. The primary endpoint was disease-free survival (DFS). Results After propensity score matching, ACT (+) was associated with significantly longer DFS than ACT (−) (HR 0.573, P = 0.003), with consistent findings for relapse-free survival, overall survival, and sensitivity analyses. Inverse probability of treatment weighting analyses showed that OX-based regimens did not achieve significantly longer DFS than did FP monotherapy (HR 1.143, P = 0.705). Exploratory subgroup analyses showed shorter DFS with OX in high-risk disease, but not in low-risk disease. Conclusions ACT was associated with improved survival, even in patients with impaired PS. In contrast, OX-based combination therapy did not demonstrate a statistically significant additional survival benefit over fluoropyrimidine monotherapy in this cohort. These findings suggest that treatment strategies for Stage III CRC with impaired PS should be individualized, with careful consideration of the patient’s condition rather than routinely intensifying treatment.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 2025
- Efficacy and safety of postoperative adjuvant chemotherapy with oxaliplatin for elderly patients: results from the CCOG-1302 studyInternational Journal of Clinical Oncology, 2025
- Impact of perioperative prognostic nutritional index changes on the survival of patients with stage II/III colorectal cancerAnnals of Gastroenterological Surgery, 2024
- Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerJAMA Oncology, 2021
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trialsThe Lancet Oncology, 2020
- Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatmentJournal of Neurology, 2020
- Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer DatabaseDiseases of the Colon & Rectum, 2016
- Adjuvant Chemotherapy for Stage III Colon CancerJAMA, 2005
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancerThe Lancet, 1995